Article Details
Retrieved on: 2024-12-09 14:43:47
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article outlines Orphagen Pharmaceuticals' funding for developing OR-812, an innovative treatment for IBD, potentially impacting diabetes-related autoimmune inflammatory bowel diseases. Tags denote related gastrointestinal and autoimmune topics, emphasizing drug mechanisms and company initiatives.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here